Wedmont Private Capital Has $3.93 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Wedmont Private Capital boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 10.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 24,651 shares of the company’s stock after purchasing an additional 2,421 shares during the period. Wedmont Private Capital’s holdings in Johnson & Johnson were worth $3,933,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Hexagon Capital Partners LLC grew its stake in shares of Johnson & Johnson by 4.9% in the 3rd quarter. Hexagon Capital Partners LLC now owns 6,055 shares of the company’s stock valued at $981,000 after buying an additional 284 shares in the last quarter. CWM LLC lifted its stake in Johnson & Johnson by 7.6% in the third quarter. CWM LLC now owns 434,670 shares of the company’s stock valued at $70,443,000 after acquiring an additional 30,666 shares during the last quarter. Brightwater Advisory LLC increased its stake in shares of Johnson & Johnson by 3.4% during the 3rd quarter. Brightwater Advisory LLC now owns 3,713 shares of the company’s stock worth $602,000 after purchasing an additional 122 shares during the last quarter. Saxon Interests Inc. raised its holdings in shares of Johnson & Johnson by 14.8% during the 3rd quarter. Saxon Interests Inc. now owns 6,823 shares of the company’s stock valued at $1,106,000 after purchasing an additional 880 shares in the last quarter. Finally, Safir Wealth Advisors LLC acquired a new stake in shares of Johnson & Johnson in the 3rd quarter valued at $220,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on JNJ. Morgan Stanley raised their target price on Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a report on Thursday, July 18th. Daiwa Capital Markets lowered Johnson & Johnson from an “outperform” rating to a “neutral” rating and reduced their target price for the stock from $160.00 to $150.00 in a report on Tuesday, July 23rd. TD Cowen dropped their price target on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research report on Thursday, July 18th. TD Securities reduced their price objective on shares of Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. Finally, Daiwa America downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $173.43.

Johnson & Johnson Stock Up 0.6 %

NYSE JNJ opened at $160.68 on Thursday. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. The stock has a market cap of $386.71 billion, a PE ratio of 10.02, a PEG ratio of 2.69 and a beta of 0.52. The firm has a 50-day simple moving average of $162.59 and a 200 day simple moving average of $154.36.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, topping the consensus estimate of $2.71 by $0.11. The company had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. Johnson & Johnson’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same quarter last year, the firm earned $2.80 EPS. On average, research analysts forecast that Johnson & Johnson will post 10.02 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.09%. The ex-dividend date was Tuesday, August 27th. Johnson & Johnson’s payout ratio is 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.